1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in the United States, July 2019

Biotechnology Analysis & Statistics in the United States, July 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • Datamonitor Healthcare

All regions

data types

1-30 of 54 reports

Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • March 2018

Overview Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic therapies. The market has been long dominated by the ...

  • Industries : Medical Biotechnology
  • Countries : European Union, United States
Drug Analysis: Cinqair

Drug Analysis: Cinqair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewCinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Drug Analysis: Fasenra

Drug Analysis: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Overview: Xolair

Drug Overview: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Dupixent

Drug Analysis: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug Overview: Dupixent

Drug Overview: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Cinqair

Drug Overview: Cinqair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewCinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Drug Overview: Fasenra

Drug Overview: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Analysis: Xolair

Drug Analysis: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical, Chronic Disease
  • Countries : United States, Japan, European Union
Market Spotlight: Myelofibrosis

Market Spotlight: Myelofibrosis

  • $ 16500
  • Industry report
  • February 2018

This Market Spotlight report covers the Myelofibrosis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence ...

  • Industries : Medical Biotechnology
  • Countries : United States, World
Drug Analysis: Provenge

Drug Analysis: Provenge

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewProvenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed ...

  • Industries : Medical Biotechnology
  • Countries : United States
Drug Overview: Provenge

Drug Overview: Provenge

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewProvenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed ...

  • Industries : Medical Biotechnology
  • Countries : United States
Drug Analysis: DCVAC/PCa

Drug Analysis: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: DCVAC/PCa

Drug Overview: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Mircera

Drug Analysis: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The drug ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Overview: Epogen

Drug Overview: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson&Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Epogen

Drug Analysis: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson and Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Aranesp

Drug Overview: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Mircera

Drug Overview: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Analysis: Aranesp

Drug Analysis: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Dengue DNA vaccine

Drug Analysis: Dengue DNA vaccine

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewThe US Naval Medical Research Center (NMRC) is developing a Vaxfectin (cationic lipid-based adjuvant; Vical)-adjuvanted, tetravalent plasmid DNA vaccine. In 2008, Vical entered into an agreement ...

  • Industries : Medical Biotechnology, Therapy
  • Countries : United States
Dengue DNA vaccine

Dengue DNA vaccine

  • $ 10000
  • Industry report
  • January 2018

Drug Overview The US Naval Medical Research Center (NMRC) is developing a Vaxfectin (cationic lipid-based adjuvant; Vical)-adjuvanted, tetravalent plasmid DNA vaccine. In 2008, Vical entered into an agreement ...

  • Industries : Medical Biotechnology, Therapy
  • Countries : United States
Crohn’s Disease: Treatment

Crohn’s Disease: Treatment

  • $ 3739
  • Industry report
  • December 2017

DescriptionDatamonitor Healthcare surveyed 240 gastroenterologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into Crohn’s disease diagnosis, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Pharmaceutical
  • Countries : United States, Japan, European Union
Drug analysis: Erbitux

Drug analysis: Erbitux

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug analysis: C-Cure

Drug analysis: C-Cure

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewC-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient’s own cells harvested ...

  • Industries : Medical Biotechnology, Chronic Disease, Biopharmaceutical, Biopharmaceutical, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Vectibix

Drug analysis: Vectibix

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewVectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents ...

  • Industries : Medical Biotechnology, Cancer, Therapy, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug analysis: Binimetinibi

Drug analysis: Binimetinibi

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewBinimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, European Union
Drug Analysis: Multikine

Drug Analysis: Multikine

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewMultikine is an investigational immunomodulator composed of a proprietary cocktail of naturally occurring cytokines such as interleukins, interferons, chemokines, and colony-stimulating factors. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug Analysis: Ofatumumab

Drug Analysis: Ofatumumab

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewOfatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumuma ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Europe
Drug Analysis: Mavenclad

Drug Analysis: Mavenclad

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewMavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms. ...

  • Industries : Medical Biotechnology
  • Countries : United States, European Union, Japan, Europe

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on